EP3810274A4 - A combination comprising fingolimod and at least one anti-epileptic agent - Google Patents

A combination comprising fingolimod and at least one anti-epileptic agent Download PDF

Info

Publication number
EP3810274A4
EP3810274A4 EP19822106.1A EP19822106A EP3810274A4 EP 3810274 A4 EP3810274 A4 EP 3810274A4 EP 19822106 A EP19822106 A EP 19822106A EP 3810274 A4 EP3810274 A4 EP 3810274A4
Authority
EP
European Patent Office
Prior art keywords
fingolimod
combination
epileptic agent
epileptic
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19822106.1A
Other languages
German (de)
French (fr)
Other versions
EP3810274A2 (en
Inventor
Ali Turkyilmaz
Merve PEKER
Emine TUNCAY
Erkin Ozturk
Muge ULUSOY BOZYEL
Yavuz Dedeoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3810274A2 publication Critical patent/EP3810274A2/en
Publication of EP3810274A4 publication Critical patent/EP3810274A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP19822106.1A 2018-06-21 2019-06-19 A combination comprising fingolimod and at least one anti-epileptic agent Withdrawn EP3810274A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201808815 2018-06-21
PCT/TR2019/050471 WO2019245512A2 (en) 2018-06-21 2019-06-19 A combination comprising fingolimod and at least one anti-epileptic agent

Publications (2)

Publication Number Publication Date
EP3810274A2 EP3810274A2 (en) 2021-04-28
EP3810274A4 true EP3810274A4 (en) 2022-03-16

Family

ID=68983746

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19822106.1A Withdrawn EP3810274A4 (en) 2018-06-21 2019-06-19 A combination comprising fingolimod and at least one anti-epileptic agent

Country Status (2)

Country Link
EP (1) EP3810274A4 (en)
WO (1) WO2019245512A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010051349A1 (en) * 2008-10-31 2010-05-06 Lexicon Pharmaceuticals, Inc. S1p receptor agonists for the treatement of cerebral malaria
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140308244A1 (en) * 2011-08-08 2014-10-16 The Board Of Trustees Of The Leland Stanford Junior University Combination Therapy for Treatment of Inflammatory Demyelinating Disease
DK3534904T3 (en) 2016-11-07 2022-04-11 Metriopharm Ag USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINDION IN THE TREATMENT OF CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010051349A1 (en) * 2008-10-31 2010-05-06 Lexicon Pharmaceuticals, Inc. S1p receptor agonists for the treatement of cerebral malaria
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALICE LARONI ET AL: "Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial", BMC NEUROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 14, no. 1, 1 April 2014 (2014-04-01), pages 65, XP021184467, ISSN: 1471-2377, DOI: 10.1186/1471-2377-14-65 *
See also references of WO2019245512A2 *

Also Published As

Publication number Publication date
WO2019245512A2 (en) 2019-12-26
WO2019245512A3 (en) 2020-06-04
EP3810274A2 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
EP3777445A4 (en) Rach numerology with bwp operation
USD741419S1 (en) Exercise band
USD771759S1 (en) Exercise band
EP4041262A4 (en) Targeted bifunctional degraders
EP3723652A4 (en) Medical tools having tension bands
EP3872117A4 (en) Flexible polyamide
EP3735608A4 (en) Eye-mounted device including a femtocamera and femtoprojector
EP3265503A4 (en) Polymeric metformin and its use as a therapeutic agent and as a delivery vehicle
EP3751048A4 (en) Fiber-treating agent
EP3976014A4 (en) A combination comprising alogliptin and metformin
EP3950010A4 (en) Continuous decontamination device
EP3893866A4 (en) A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent
ZA201906271B (en) Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicament
EP3738601A4 (en) Cytocidal agent
EP3769759A4 (en) Epilepsy treatment agent
EP3810274A4 (en) A combination comprising fingolimod and at least one anti-epileptic agent
EP4039328A4 (en) Dysuria-alleviating agent
EP3831399A4 (en) Anti-norovirus agent
SI3740191T1 (en) Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
SG11202006539RA (en) Cytocidal agent
GB201801895D0 (en) Medicament packaging assembly
EP3573994A4 (en) Cysteamine prodrugs
EP3810112A4 (en) A combination comprising fingolimod and modafinil
EP3810110A4 (en) A combination comprising fingolimod and amantadine
EP3902531A4 (en) Pharmaceutical combinations comprising fingolimod and a spasmolytic

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201225

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0025000000

Ipc: A61K0031137000

A4 Supplementary search report drawn up and despatched

Effective date: 20220216

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/48 20060101ALI20220210BHEP

Ipc: A61K 9/20 20060101ALI20220210BHEP

Ipc: A61K 45/06 20060101ALI20220210BHEP

Ipc: A61P 25/28 20060101ALI20220210BHEP

Ipc: A61K 31/197 20060101ALI20220210BHEP

Ipc: A61K 31/195 20060101ALI20220210BHEP

Ipc: A61K 31/714 20060101ALI20220210BHEP

Ipc: A61P 25/08 20060101ALI20220210BHEP

Ipc: A61P 37/06 20060101ALI20220210BHEP

Ipc: A61P 25/00 20060101ALI20220210BHEP

Ipc: A61K 31/137 20060101AFI20220210BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220920